Gilead Sciences (NASDAQ:GILD) PT Lowered to $105.00

Gilead Sciences (NASDAQ:GILDFree Report) had its price target lowered by Oppenheimer from $115.00 to $105.00 in a research note issued to investors on Monday morning, Benzinga reports. Oppenheimer currently has an outperform rating on the biopharmaceutical company’s stock.

Several other equities research analysts have also weighed in on GILD. Deutsche Bank Aktiengesellschaft began coverage on shares of Gilead Sciences in a report on Thursday, November 9th. They issued a hold rating and a $75.00 target price on the stock. UBS Group lowered their price objective on shares of Gilead Sciences from $85.00 to $84.00 and set a neutral rating for the company in a research report on Wednesday, November 8th. Wells Fargo & Company lowered their price objective on shares of Gilead Sciences from $90.00 to $84.00 and set an equal weight rating for the company in a research report on Wednesday, February 7th. Cantor Fitzgerald lowered their price objective on shares of Gilead Sciences from $80.00 to $78.00 and set a neutral rating for the company in a research report on Wednesday, February 7th. Finally, Barclays increased their price objective on shares of Gilead Sciences from $82.00 to $85.00 and gave the stock an equal weight rating in a research report on Tuesday, January 23rd. One analyst has rated the stock with a sell rating, eight have given a hold rating, six have issued a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat.com, Gilead Sciences has an average rating of Hold and an average target price of $87.36.

View Our Latest Research Report on Gilead Sciences

Gilead Sciences Trading Up 1.1 %

GILD opened at $74.45 on Monday. The firm’s fifty day moving average is $80.67 and its two-hundred day moving average is $78.19. The company has a debt-to-equity ratio of 1.08, a quick ratio of 1.16 and a current ratio of 1.46. The firm has a market cap of $92.77 billion, a PE ratio of 16.54, a price-to-earnings-growth ratio of 0.96 and a beta of 0.20. Gilead Sciences has a twelve month low of $72.81 and a twelve month high of $87.86.

Gilead Sciences (NASDAQ:GILDGet Free Report) last posted its earnings results on Tuesday, February 6th. The biopharmaceutical company reported $1.72 earnings per share for the quarter, missing the consensus estimate of $1.76 by ($0.04). The firm had revenue of $7.12 billion during the quarter, compared to analyst estimates of $7.10 billion. Gilead Sciences had a return on equity of 38.85% and a net margin of 20.89%. The company’s revenue for the quarter was down 3.7% on a year-over-year basis. During the same quarter last year, the business posted $1.67 earnings per share. Equities research analysts anticipate that Gilead Sciences will post 7.08 EPS for the current year.

Gilead Sciences Increases Dividend

The firm also recently declared a quarterly dividend, which will be paid on Thursday, March 28th. Shareholders of record on Friday, March 15th will be paid a $0.77 dividend. This is a positive change from Gilead Sciences’s previous quarterly dividend of $0.75. This represents a $3.08 annualized dividend and a yield of 4.14%. The ex-dividend date is Thursday, March 14th. Gilead Sciences’s payout ratio is presently 66.67%.

Insider Buying and Selling at Gilead Sciences

In other news, CFO Andrew D. Dickinson sold 5,000 shares of the business’s stock in a transaction dated Tuesday, January 16th. The shares were sold at an average price of $85.78, for a total transaction of $428,900.00. Following the transaction, the chief financial officer now directly owns 101,534 shares in the company, valued at approximately $8,709,586.52. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. In other news, insider Johanna Mercier sold 8,242 shares of the business’s stock in a transaction dated Tuesday, January 9th. The shares were sold at an average price of $85.23, for a total transaction of $702,465.66. Following the transaction, the insider now directly owns 82,729 shares in the company, valued at approximately $7,050,992.67. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CFO Andrew D. Dickinson sold 5,000 shares of the business’s stock in a transaction dated Tuesday, January 16th. The stock was sold at an average price of $85.78, for a total transaction of $428,900.00. Following the transaction, the chief financial officer now owns 101,534 shares in the company, valued at $8,709,586.52. The disclosure for this sale can be found here. Company insiders own 0.21% of the company’s stock.

Institutional Trading of Gilead Sciences

Hedge funds and other institutional investors have recently modified their holdings of the stock. The Manufacturers Life Insurance Company boosted its holdings in shares of Gilead Sciences by 1.4% during the 2nd quarter. The Manufacturers Life Insurance Company now owns 4,188,890 shares of the biopharmaceutical company’s stock worth $322,838,000 after buying an additional 56,363 shares during the period. Commonwealth Equity Services LLC boosted its holdings in shares of Gilead Sciences by 1.5% during the 2nd quarter. Commonwealth Equity Services LLC now owns 346,600 shares of the biopharmaceutical company’s stock worth $26,713,000 after buying an additional 5,266 shares during the period. Abundance Wealth Counselors bought a new stake in shares of Gilead Sciences during the 3rd quarter worth about $1,881,000. Savant Capital LLC boosted its holdings in shares of Gilead Sciences by 1.3% during the 2nd quarter. Savant Capital LLC now owns 26,776 shares of the biopharmaceutical company’s stock worth $2,064,000 after buying an additional 356 shares during the period. Finally, Itau Unibanco Holding S.A. boosted its holdings in shares of Gilead Sciences by 50.6% during the 2nd quarter. Itau Unibanco Holding S.A. now owns 3,713 shares of the biopharmaceutical company’s stock worth $286,000 after buying an additional 1,247 shares during the period. Institutional investors own 82.33% of the company’s stock.

About Gilead Sciences

(Get Free Report)

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of coronavirus disease 2019; and Epclusa, Harvoni, Vosevi, Vemlidy, and Viread for the treatment of viral hepatitis.

Further Reading

Analyst Recommendations for Gilead Sciences (NASDAQ:GILD)

Receive News & Ratings for Gilead Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences and related companies with MarketBeat.com's FREE daily email newsletter.